What you should know:
1. The guideline, published in Gastroenterology, navigates the increased number of therapies available for the long-term management of moderate to severe ulcerative colitis.
2. The guideline focuses on immunomodulators, biologics and small molecules that lead to remission and decrease colectomy risk.
3. There is no cure for UC, but quality of life increases when the disease is in remission.
Read the entire guideline here.
More articles on surgery centers:
Nevada city drops ASC building acquisition to let health system buy it
Insights from the CEOs of Optum, USPI, Surgery Partners & more — 8 ASC industry notes
Why Texas’ ASC market is booming — 4 center leaders elaborate
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
